Table 3.
Features | PFS (Months) |
---|---|
M Stage | |
M1a | 8 (3–30) |
M1b | 3 (3–36.5) |
M1c | 3 (2–3) |
M1d | 2 (2–3) |
ECOG | |
0 | 9 (3–32) |
1 | 3 (2–5) |
2 | 2 (2–3) |
LDH | |
<ULN | 3 (3–27) |
≥ULN | 3 (2–3) |
Number of Metastatic Sites | |
< 3 | 3 (3–24) |
≥3 | 3 (2–3) |
Features | PFS (Months) |
---|---|
M Stage | |
M1a | 8 (3–30) |
M1b | 3 (3–36.5) |
M1c | 3 (2–3) |
M1d | 2 (2–3) |
ECOG | |
0 | 9 (3–32) |
1 | 3 (2–5) |
2 | 2 (2–3) |
LDH | |
<ULN | 3 (3–27) |
≥ULN | 3 (2–3) |
Number of Metastatic Sites | |
< 3 | 3 (3–24) |
≥3 | 3 (2–3) |